[1]. Li Z, Zhao T, Tan X, Lei S, Huang L, Yang L: Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3, and KCNJ1 are Associated with Serum Lipid Profile in Chinese Han Population. Int J Environ Res Public Health 2019, 16(17): 3207.
[2]. Chu J GR, Zhao S, et al. : Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised edition in 2016). Chinese Circulation Journal 2016, 31(10):937-953.
[3]. Sarzynski MA, Schuna JM, Jr., Carnethon MR, Jacobs DR, Jr., Lewis CE, Quesenberry CP, Jr., Sidney S, Schreiner PJ, Sternfeld B: Association of Fitness With Incident Dyslipidemias Over 25 Years in the Coronary Artery Risk Development in Young Adults Study. Am J Prev Med 2015, 49(5):745-752.
[4]. Pantos J, Efstathopoulos E, Katritsis DG: Vascular wall shear stress in clinical practice. Curr Vasc Pharmacol 2007, 5(2):113-119.
[5]. Ciccone MM, Miniello V, Marchioli R, Scicchitano P, Cortese F, Palumbo V, Primitivo SG, Sassara M, Ricci G, Carbonara S et al: Morphological and functional vascular changes induced by childhood obesity. Eur J Cardiovasc Prev Rehabil 2011, 18(6):831-835.
[6]. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl 2):S1-45.
[7]. He C, Fu P, Zhang K, Xia Q, Yang Y, Xie L: Chinese herbal medicine for dyslipidemia: protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2018, 97(44):e13048.
[8]. Eelen G, Treps L, Li X, Carmeliet P: Basic and Therapeutic Aspects of Angiogenesis Updated. Circ Res 2020, 127(2):310-329.
[9]. Scicchitano P, Cortese F, Gesualdo M, De Palo M, Massari F, Giordano P, Ciccone MM: The role of endothelial dysfunction and oxidative stress in cerebrovascular diseases. Free Radic Res 2019, 53(6):579-595.
[10]. Chen J YC, Yang Z , et al: The correlation between the traditional Chinese medicine (TCM) syndrome and the concentration of adiponectin and peroxynitrite in dyslipidemia patients. European Journal of Integrative Medicine 2016, 8(6):973-979.
[11]. Davies LC, Taylor PR: Tissue-resident macrophages: then and now. Immunology 2015, 144(4):541-548.
[12]. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, Thompson RW, Cheever AW, Murray PJ, Wynn TA: Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009, 5(4):e1000371.
[13]. Moore EM, West JL: Harnessing Macrophages for Vascularization in Tissue Engineering. Ann Biomed Eng 2019, 47(2):354-365.
[14]. Yamada Y, Doi T, Hamakubo T, Kodama T: Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci 1998, 54(7):628-640.
[15]. Jiang TT, Li JC: Review on the systems biology research of Yin-deficiency-heat syndrome in traditional Chinese medicine. Anat Rec (Hoboken) 2020. doi: 10.1002/ar.24354.
[16]. Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV: Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. Diabetes Care 2017, 40(4):529-537.
[17]. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ et al: Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015, 131(4):e29-322.
[18]. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, Song Y, Lim JH, Kim HJ, Choi S et al: 2018 Guidelines for the management of dyslipidemia in Korea. Korean J Intern Med 2019, 34(5):1171.
[19]. Sham TT, Chan CO, Wang YH, Yang JM, Mok DK, Chan SW: A review on the traditional Chinese medicinal herbs and formulae with hypolipidemic effect. Biomed Res Int 2014, 2014:925302.
[20]. Bei WJ, Guo J, Wu HY, Cao Y: Lipid-regulating effect of traditional chinese medicine: mechanisms of actions. Evid Based Complement Alternat Med 2012, 2012:970635.
[21]. Chen J, Ye C, Hu X, Huang C, Yang Z, Li P, Wu A, Xue X, Lin D, Yang H: Serum metabolomics model and its metabolic characteristics in patients with different syndromes of dyslipidemia based on nuclear magnetic resonance. J Pharm Biomed Anal 2019, 167:100-113.
[22]. Tiwari RL, Singh V, Barthwal MK: Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 2008, 28(4):483-544.
[23]. Ng CT, Fong LY, Sulaiman MR, Moklas MA, Yong YK, Hakim MN, Ahmad Z: Interferon-Gamma Increases Endothelial Permeability by Causing Activation of p38 MAP Kinase and Actin Cytoskeleton Alteration. J Interferon Cytokine Res 2015, 35(7):513-522.
[24]. Chrobak I, Lenna S, Stawski L, Trojanowska M: Interferon-gamma promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) beta2. J Cell Physiol 2013, 228(8):1774-1783.
[25]. Schroecksnadel K, Frick B, Winkler C, Fuchs D: Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006, 4(3):205-213.
[26]. Buttmann M, Berberich-Siebelt F, Serfling E, Rieckmann P: Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells. J Vasc Res 2007, 44(1):51-60.
[27]. Kobayashi T, Takaku Y, Yokote A, Miyazawa H, Soma T, Hagiwara K, Kanazawa M, Nagata M: Interferon-beta augments eosinophil adhesion-inducing activity of endothelial cells. Eur Respir J 2008, 32(6):1540-1547.
[28]. Boshuizen MC, Hoeksema MA, Neele AE, van der Velden S, Hamers AA, Van den Bossche J, Lutgens E, de Winther MP: Interferon-beta promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms. Cytokine 2016, 77:220-226.
[29]. Liehn EA, Zernecke A, Postea O, Weber C: Chemokines: inflammatory mediators of atherosclerosis. Arch Physiol Biochem 2006, 112(4-5):229-238.
[30]. Weber C, Zernecke A, Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008, 8(10):802-815.
[31]. Kleemann R, Zadelaar S, Kooistra T: Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 79(3):360-376.
[32]. Cicha I, Regler M, Urschel K, Goppelt-Struebe M, Daniel WG, Garlichs CD: Resveratrol inhibits monocytic cell chemotaxis to MCP-1 and prevents spontaneous endothelial cell migration through Rho kinase-dependent mechanism. J Atheroscler Thromb 2011, 18(12):1031-1042.
[33]. Xue SS, He JL, Zhang X, Liu YJ, Xue FX, Wang CJ, Ai D, Zhu Y: Metabolomic analysis revealed the role of DNA methylation in the balance of arachidonic acid metabolism and endothelial activation. Biochim Biophys Acta 2015, 1851(10):1317-1326.
[34]. Jensen LD, Hansen AJ, Lundbaek JA: Regulation of endothelial cell migration by amphiphiles - are changes in cell membrane physical properties involved? Angiogenesis 2007, 10(1):13-22.
[35]. Rukoyatkina N, Shpakova V, Panteleev M, Kharazova A, Gambaryan S, Geiger J: Multifaceted effects of arachidonic acid and interaction with cyclic nucleotides in human platelets. Thromb Res 2018, 171:22-30.
[36]. Jantke J, Ladehoff M, Kurzel F, Zapf S, Kim E, Giese A: Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir (Wien) 2004, 146(5):483-494.
[37]. Wang W, Yang L, Song L, Guo M, Li C, Yang B, Wang M, Kou N, Gao J, Qu H et al: Combination of Panax notoginseng saponins and aspirin potentiates platelet inhibition with alleviated gastric injury via modulating arachidonic acid metabolism. Biomed Pharmacother 2021, 134:111165.
[38]. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002, 82(1):131-185.
[39]. Spiecker M, Liao JK: Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005, 433(2):413-420.
[40]. Xu X, Zhang XA, Wang DW: The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 2011, 63(8):597-609.
[41]. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285(5431):1276-1279.
[42]. Bellien J, Iacob M, Remy-Jouet I, Lucas D, Monteil C, Gutierrez L, Vendeville C, Dreano Y, Mercier A, Thuillez C et al: Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation 2012, 125(10):1266-1275.
[43]. Potente M, Gerhardt H, Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell 2011, 146(6):873-887.
[44]. Alvarez Arroyo MV, Caramelo C, Angeles Castilla M, Gonzalez Pacheco FR, Martin O, Arias J: Role of vascular endothelial growth factor in the response to vessel injury. Kidney Int Suppl 1998, 68:S7-9.
[45]. Jeong HW, Hernandez-Rodriguez B, Kim J, Kim KP, Enriquez-Gasca R, Yoon J, Adams S, Scholer HR, Vaquerizas JM, Adams RH: Transcriptional regulation of endothelial cell behavior during sprouting angiogenesis. Nat Commun 2017, 8(1):726.
[46]. Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, Roers A, Eming SA: Differential roles of macrophages in diverse phases of skin repair. J Immunol 2010, 184(7):3964-3977.
[47]. Corliss BA AM, Munson JM,et al: Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis. Microcirculation 2016, 23(2):95-121.
[48]. Dvorak HF: Angiogenesis: update 2005. J Thromb Haemost 2005, 3(8):1835-1842.
[49]. Guo L, Akahori H, Harari E, Smith SL, Polavarapu R, Karmali V, Otsuka F, Gannon RL, Braumann RE, Dickinson MH et al: CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. J Clin Invest 2018, 128(3):1106-1124.
[50]. Zachary I: VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003, 31(Pt 6):1171-1177.